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http://dx.doi.org/10.1016/j.jmii.2012Background: Hepatitis C virus (HCV) is a major cause of acute and chronic liver disease.
Numerous screening assays based on the detection of immunoresponses to HCV structural
and nonstructural proteins have been designed. Various studies have demonstrated
genotype-specific differences in anti-HCV antibody responses to different HCV proteins.
Methods: Full-length NS3 protease and N-terminally truncated NS5A were expressed using pET
TOPO 102/D system. Antigenicity of the purified recombinant proteins was assessed by immu-
noblotting and indirect enzyme-linked immunosorbent assay (ELISA). Furthermore, anti-HCV
antibody responses to the recombinant proteins were evaluated in three prevalent genotypes
in Iran.
Results: We were able to express and purify NS5A and NS3 protease using TOPO cloning system.
The HCV NS3 protease and NS5A produced in BL21 Star (DE3) was immunoreactive. Our results
demonstrate that NS3 protease and NS5A have good immunoreactivity, but they are not suffi-
cient for detecting all HCV-positive sera. No significant genotype-specific differences were de-
tected in immunoresponses to the recombinant proteins.
Conclusion: In conclusion, we successfully isolated, expressed, and purified substantial
amount of HCV NS3 protease and N-terminally truncated NS5A, and used them as capturing
antigens in a screening ELISA assay with high sensitivity, reproducibility, and specificity.t of Medical Biotechnology, Faculty of Allied Medical Sciences & Cellular and Molecular Research
Sciences, Hemmat Highway, Tehran, Iran.
.ir (M.M. Farajollahi).
to this work.
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Immunoreactivity assessment of HCV proteins 283Figure 1. HCV genome anAccordingly, it is well confirmed that TOPO cloning system can be used as a dynamic system in
order to express higher amount of immunoreactive viral proteins.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Currently, 3% of the world’s population is infected with
hepatitis C virus (HCV).1 HCV is the major cause of post-
transfusion non-A, non-B hepatitis,2,3 and can also cause
both acute and chronic hepatitis.1 Approximately 200
million people suffer chronically from hepatitis C, which
may finally lead to occurrence of progressive liver diseases
such as cirrhosis and hepatocellular carcinoma.4
HCV is a small enveloped virus; it is classified into Fla-
viviridae family and Hepacivirus genus.5e7 Isolated hepa-
titis viruses are further classified into six genotypes (1e6),
and variable subtypes within each genotype.8 The genome
of HCV is a single positive-stranded RNA of 9.6 kb size. Viral
RNA does not have polyA and 50 cap.9,10 RNA genome
consists of a single open reading frame located between
two noncoding regions.11 The 50 non-coding region contains
an internal ribosome entry site, which makes cap-
independent translation possible.11
The viral RNA is directly translated to a precursor poly-
protein with 3010e3030 amino acids.12 This polyprotein is
co- and post-translationally cleaved by host and viral
proteases (Fig. 1).13,14 These cleavages are necessary for
maturation of four structural and six nonstructural viral
proteins.15 HCV structural proteins are as follows: core
protein, E1, E2, and P7. These proteins are further cleaved
by cellular signal peptidase.15 NS2eNS3 autoprotease
catalyzes the cleavage between NS2 and NS3, while the
other structural proteins are cleaved by NS3 protease.16
HCV NS3 is a 70 kDa multifunctional enzyme that
contains a serine protease domain in its N terminus and an
NTPase/helicase domain in the C terminus.17,18 The N-
terminal 181 amino acid of NS3 protein has a serine
protease activity, and it is the key enzyme for cis and trans
cleavage of the nonstructural proteins,9,19 except for the
incision of NS2 and NS3.17,18 X-ray crystallography hasd polyprotein structure. HCV Zshown that NS3 serine protease has a double b-barrel
folding, which is similar to the other serine proteases of
chymotrypsin/trypsin superfamily.20,21
The active catalytic site of NS3 protease consists of
three highly conserved amino acid residuesdHis: 57, Asp:
81, and Ser: 139. This site is located between two b-barrel
folds.21,22 The substrate-binding groove is a shallow
solvent-exposed pocket.23,24 HCV NS3 protease is a zinc-
binding serine protease.25 However, zinc ion is not
involved in the catalytic mechanism and is located far away
from the active site. Zinc is considered to have a structural
role; thus, it is essential for the structural integrity of the
enzyme.26
NS5A is a phosphoprotein with a molecular weight of
56e58 kDa. It consists of three domains: domain Ι
(1e213aa), domain ΙΙ (250e342aa), and domain ΙΙΙ
(356e447aa).27 Domain Ι contains the N-terminal
membrane-anchoring helix and was proven to have a critical
role in mediating the association of NS5A with the endo-
plasmic reticulum (ER) membrane.28 There are two regions
within domain ΙΙ (237e276aa) and domain III (359e407aa),
called ISDR [interferon (IFN) sensitivity-determining region]
and IRRDR (IFN/ribavirin resistance-determining region).
HCV ISDR and IRRDR are responsible for resistance to IFN and
ribavirin therapy. NS5A has been shown to modulate the IFN
response by interaction with double-strand RNA-dependent
protein kinase, 2-5 oligoadenylate synthetase, and other
host cell proteins via ISDR and IRRDR.27,29,30 Although no
enzymatic activity has been reported for NS5A, many of the
studies reveal that it plays essential roles in HCV replication
and assembly, and host cell growth and proliferation.30,31
Interaction between NS5A and many of the host cellular
proteins and signaling pathways generated most attention in
HCV investigation.27,32
HCV infection generates antibodies against all viral
proteins, which can be used in the diagnosis of HCVhepatitis C virus; IRES Z internal ribosome entry site.
Table 1 Primers used for nested PCR
Primer name Sequence
Outer-Forward-NS3
protease
50-CGGGACTGGGCGCATAACG-30
Outer-Reverse-NS3
protease
50-GACCCCGTGGGCCTTGGAC-30
Inner-Forward-NS3
protease
50-CACCCTGGCGCCCATCAC-30
Inner-Reverse-NS3
protease
50-TGCTGGTGGAGAGGAGTTGTC-30
Outer-Forward-NS5A 50-GCACCAGTGGATAAGCTCGGA-30
Outer-Reverse-NS5A 50-GCAACGAGTTGCTCAGTGCGT-30
Inner-Forward-NS5A 50-CACCAAGCTCATGCCACAACTG-30
Inner-Reverse-NS5A 50-GCAGCACACGACGTCCTCC-30
PCR Z polymerase chain reaction.
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patient sera. This early immunoreactivity of NS3 protease
makes it a suitable antigen for developing first-, second-,
and third-generation enzyme-linked immunosorbent assay
(ELISA) kits.33 Limited genetic variation of NS3 protease
makes it an appropriate target for the design of vaccines
against HCV.34 Furthermore, many lines of evidence sug-
gested that different regions in HCV NS5A were confirmed
to be suitable and effective antigens for evaluating the
presence of antibodies against HCV.35e37 Early detection of
anti-NS5A antibodies in sera would be a beneficial approach
to diagnose the HCV infection.38
In the current study, we demonstrate a method for
expressing and purifying thioredoxin-tagged NS3 protease
and NS5A. It is noteworthy that most articles did not
specifically report the protein yield of the mentioned
proteins. In this study, we describe a developed procedure
for expressing a high level of recombinant HCV proteins in
BL21 Star (DE3) Escherichia coli strain under the control of
T7 promoter. We further investigate the ability of each
recombinant protein, as an antigen, to detect HCV anti-
bodies in samples of patients with hepatitis and healthy
blood donors using indirect ELISA method and immuno-
blotting. First, we measured serological reactivity to each
recombinant HCV protein. Second, we assessed immunor-
esponses to both antigens. We also studied antibody
responses in various HCV genotypes so as to analyze the
specificity of immune response against the antigen in
different genotypes. For this purpose, we evaluated sero-
logical reactivity of the most prevalent HCV genotypes in
Iran to antigens derived from HCV genotype 1a.
Materials and methods
Human sera
Blood samples of HCV-infected patients were collected
from Iranian Blood Transfusion Organization. Samples were
centrifuged and sera were separated. All sera were tested
for the presence of antibodies to HCV using third-
generation ELISA kit (Hepanostika HCV Ultra, BioMerieux,
Marcy I’Etoile, France). Positive results of HCV antibody
were certified by recombinant immunoblot assay (RIBA)
assay. Anti-HCV-positive samples were subsequently sub-
jected to qualitative polymerase chain reaction (PCR) in
order to detect viral RNA. Infecting HCV genotype was
determined using HCV genotyping kit (Sacace, Como, Italy).
HCV RNA extraction and cDNA synthesis
Isolated RNA was subjected to one-step reverse transcrip-
tase (RT) PCR using Roche transcriptor high-fidelity cDNA
synthesis kit, according to the manufacturer’s manual.
Nested PCR for amplification of NS3 protease gene
and NS5A
In the current work, NS3 protease and NS5A genes were
isolated from HCV-positive serum sample of an Iranian
patient infected with genotype 1a. Previously, NS3-helicasegene of HCV genotype 1a was amplified in our laboratory
and it was sequenced. Basic local alignment search tool
(BLAST) results demonstrated that the most similar
submitted sequence to the isolated genotype was
EU687194.1. Primer pairs used in the present study were
designed on the basis of the same sequence.
Coding regions of NS3 protease and NS5A were amplified
by nested PCR using two different sets of primers for each
gene (Table 1). The outer primer set was designed to amplify
a larger region containing the coding sequence, and the
inner primers were hybridized completely to the target
genes. To enable directional cloning, the forward PCR primer
contains the sequence, CACC, at the 50 end of the primer.
The first PCR reaction was assembled on ice in a final
volume of 50 mL using the following reagents: 5 mL PCR buffer
containing MgSO4 at a concentration of 20 mM, 0.5 mg cDNA,
1 mM of each of the outer primers, deoxyribonucleotide
triphosphate (dNTP) mix containing 0.2 mM of each of the
dNTPs, and 1 U of Pfu DNA polymerase (Fermentas #EP0571).
A second PCR was performed on the product of the
earlier PCR using inner primers (Table 1) using the previ-
ously described protocol. Inner primers were used instead
of outer set, and 2 mL of the first PCR product was used as
template. The same thermal cycling condition was applied
except for the annealing time, which was set to 45 seconds
for NS3 protease and 90 seconds for NS5A.
PCR product fragments were extracted from agarose gel
after electrophoresis with Qiagen QIAquick gel extraction
kit, according to the manufacturer’s instruction.
TOPO cloning (construction of NS3 protease and
NS5a expression plasmids)
The recovered PCR product fragments were directly cloned
into pET102/D-TOPO (Invitrogen, Montreal, Canada). Liga-
tion products were transformed into E. coli TG1. The
transformed bacteria with recombinant plasmids would be
resistant to ampicillin. Thus, Luria Bertani (LB) agar plates
containing ampicillin (100 mg/mL) were used for selecting
transformants.
Colonies from agar plate were subjected to plasmid
extraction using Roche High Pure Plasmid Isolation Kit,
according to the manufacturer’s manual. In order to
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plasmids were sequenced (Bioneer, Daejeon, South Korea).
All constructs were expressed with an N-terminal His-
patch thioredoxin and C-terminal V5-epitope and 6x-His
tag.
Expression of recombinant full-length NS3 protease
and N-terminally truncated NS5A
BL21 Star (DE3)-competent cells were separately trans-
formed with 10 ng of each plasmid by heat shock. Bacteria
bearing one of the recombinant plasmid were grown over-
night with shaking at 37C in 10 mL of LB broth medium
containing 100 mg/mL ampicillin.
Overnight cultures were diluted 1/50 in fresh LB broth
medium containing 100 mg/mL ampicillin and shaken at
37C for expressing NS3 protease, while the culture of
bacteria containing NS5A recombinant plasmids was shaken
at room temperature. The cells were grown to an OD600 of
w0.6, followed by induction with isopropyl-b-D-thio-
galactopyranoside (IPTG). IPTG was added to the final
concentration of 1 mM. The cells were incubated at 37C
with gentle shaking for an additional 4 hours. Expression of
NS5A was also induced by 1 mM IPTG at 24C in order to
harvest soluble form of NS5A, since at temperatures above
30C NS5A is insoluble. After induction, cells were har-
vested by centrifugation at 4000 rpm at 4C for 15 minutes.
Total RNA purification and real-time RT PCR
Harvested cells were resuspended in 800 mL lysis buffer
(pH Z 8.0), containing 80 mL sodium dodecyl sulfate,
lysozyme 0.5 mg/mL, RNase inhibitor 2.5 mL, and phenol
1.25 mL in TE buffer. The prepared suspensions were
incubated in a water bath at 64C for 4 minutes. TRIZOL
reagent (5 mL) was added to each tube and incubated at
room temperature for 5 minutes. Afterward, 2 mL of cold
chloroform was added and the tube was shaken vigorously
for 15 seconds. After 2 minutes’ incubation at RT, tubes
were centrifuged at 12,000g for 15 minutes at 4C. Aqueous
layer was carefully transferred to a new sterile tube. The
RNA was precipitated by adding 5 mL of cold isopropanol
and centrifugation at 12,000g for 10 minutes at 4C. The
supernatant was discarded and the pellets were resus-
pended in 5 mL of 75% ethanol. The tubes were centrifuged
at 7500g for 5 minutes at 4C. After discarding the super-
natant, the pellets were air dried and dissolved in 30 mL of
diethylpyrocarbonate water. Absorbance of each sample
was determined at 260 nm by spectrophotometer, and the
OD260/OD280 ratio was calculated.
After cDNA synthesis, real-time PCR was performed in
order to detect the presence of NS3 protease and NS5A
mRNAs. Real-time PCR reactions were prepared according
to Roche lightcycler faststart DNA master SYBR Green Ι
manual. A negative control was run in parallel with the
duplicate samples.
Purification of NS3 protease and NS5A
The recombinant proteins were purified with two different
procedures.First purification method: The cell pellet was resus-
pended in 8 mL of binding buffer, pH Z 8.0 (containing
50 mM NaH2PO4, pH Z 8.0; 0.5 M NaCl; and 10 mM imid-
azole, pH Z 6.0). Then 8 mg lysozyme and 1 mM phenyl-
methylsulfonyl fluoride were added to the suspension, and
it was incubated on ice for 30 minutes. Afterward, the
suspension was lysed by sonication using six 10-second
bursts at high intensity, with a 10-second pause between
each burst. Sonication was done on ice. The lysate was
centrifuged at 4000 rpm for 15 minutes at 4C. Supernatant
containing the recombinant protein was removed, and the
protein was purified by Ni-NTA agarose affinity column.
Lysate was added to the Ni-NTA column prepared by
washing with binding buffer twice. Column was gently
rocked for 60 minutes followed by centrifugation at 800g,
and supernatant was carefully aspirated. The column was
washed three times with wash buffer, pHZ 8.0 (containing
50 mM NaH2PO4, pH Z 8.0; 0.5 M NaCl; and 20 mM imid-
azole, pH Z 6.0). Finally, the recombinant protein was
collected by washing the column with elution buffer,
pH Z 8.0 (containing 50 mM NaH2PO4, pH Z 8.0; 0.5 M
NaCl; and 250 mM imidazole, pH Z 6.0).
Second purification method: The cell pellet was resus-
pended in 8 mL of guanidinium lysis buffer, PH Z 7.8
(containing 6 M guanidine hydrochloride, 20 mM sodium
phosphate, and 0.5 M NaCl). For preparing cell lysate, the
pellet was gently rocked for 10 minutes at 24C. The cell
lysate was sonicated on ice with five 10-second bursts at
high intensity, with a 10-second pause between each burst.
To pellet the cellular debris the suspension was centrifuged
at 4000 rpm for 15 minutes, and the supernatant was
transferred to a sterile tube. The Ni-NTA column was
washed with 6 mL of denaturing binding buffer (containing
8 M urea, 20 mM sodium phosphate, and 0.5 mM NaCl). The
cell lysate was added to the prepared Ni-NTA column, and
the column was gently rotated for 30 minutes and then
centrifuged at 800g; the supernatant was aspirated and the
resin was agitated in 4 mL of denaturing binding buffer for 2
minutes, followed by centrifugation at 800g. Afterward,
the column was washed with 4 mL of denaturing wash
buffer, pH Z 6.0 (containing 8 M urea, 20 mM sodium
phosphate, and 0.5 mM NaCl). Subsequently, the column
was washed with native wash buffer, and finally the
recombinant protein was eluted with native elution buffer.
All fractions were stored at 4C prior to analyzing by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and western blot.
Protein assay
Protein concentration of each sample was quantified by
performing bicinchoninic acid (BCA) protein assay using
Pierce Micro BCA protein assay kit, according to the
manufacturer’s instructions.
ELISA for detection of antibodies to NS3 protease
and NS5A
Full-length purified NS3 protease and N-terminally trun-
cated NS5A were analyzed for their immunoreactivity using
indirect ELISA test. Recombinant proteins were used
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carbonate buffer (0.5 mg/mL, pHZ 9.6) for capturing anti-
HCV antibodies in sera. After optimizing the test condition,
100 HCV-positive sera (unknown genotypes) and 50 healthy
samples were tested using indirect ELISA method.
Furthermore, antibody responses were assessed in three
different genotypes, 1a, 1b, and 3a, so as to determine the
specificity of each recombinant antigen and investigate
immune response variations in different genotypes.
Reproducibility of the test was assessed by repeating the
ELISA assay by two different operators.
Results
Gene amplification, TOPO cloning, and sequencing
PCR-amplified NS3 protease and NS5A were subjected to
agarose gel electrophoresis, and the expected fragments
were verified to be of 573 and 1269 bp, respectively. Since
the PCR products were subjected to directional TOPO
cloning in pET vector that has an ampicillin-resistance
gene, the efficiency of bacterial transformation was
approved by colony formation on LB agar plate containing
100 mg/mL ampicillin. Accuracy of ligated DNA fragments
with vector has been determined by performing PCR on
bacterial colonies and sequencing in both directions using
forward and reverse primers.
Phylogenetic comparison of NS3 protease and NS5A
isolated from Iranian patients infected with HCV
genotype 1a with other submitted sequences in
genebank
Complete sequence of NS3 protease and NS5A genes was
aligned with submitted sequences of six different HCV
genotypes in NCBI database, and the final phylogenetic tree
was drawn using the neighbor-joining method with clus-
talW2. The tree was obtained when neutral unbiased
correction for multiple situations was turned on. Phyloge-
netic comparison and branching analysis revealed that the
isolated sequence belongs to genotype 1a (Fig. 2).
Although the primers were designed on the basis of HCV
subtype 1a (genebank accession number, EU687194.1), thisFigure 2. Multiple sequence alignment of (A) isolated NS3 protea
isolated sequence has the same root with hepatitis C virus genotypsubtype was not isolated from the sera. Sequence analysis of
the isolated genes revealed that the genes were originated
fromanewvariantof theHCVrelated tosubtype1a.According
to the multiple sequence alignment, the closest sequence to
Iranian 1a isolate is EU482871.1, which was isolated in Ten-
nessee, USA. In the NS3 protease region, only five amino acids
differed from another submitted 1a sequence. The truncated
NS5A sequence exhibited more variability and differed from
the published genotype 1a by 17 amino acids (Fig. 3).Heterogeneity analysis of NS3 protease and NS5A
amino acid sequences
The amino acid sequence of recombinant proteins were
derived from the nucleotide sequence of the cloned frag-
ments and were compared with other published sequences
of the same regions of other HCV genotypes (Fig. 3).
Multiple sequence alignment revealed that the amino
acid sequences from the same genotype were very similar,
although those from other published genotypes were
different. For instance, maximum identity of the recombi-
nant proteins with genotype 3a is only 68%, but conservation
of the catalytic triad, binding residues, and zinc-binding site
of NS3 protease was verified. The most similar sequences to
our isolate were 1a, 5a, and 6a, respectively.Expression, real-time PCR, and western blot
Successful transcription of NS3 protease and NS5A was
identified by real-time PCR using SYBER Green and specific
inner primers. Specificity of the amplified PCR product was
proved by performing a melting curve analysis. Melting
curve analysis resulted in single product-specific tempera-
ture for NS3 protease and NS5A.
The NS3 protease and NS5A were expressed with N-
terminal His-patch thioredoxin tag in order to improve the
solubility, which was a successful strategy in the case of
NS5A, but the solubility of NS3 protease still remained low.
Authenticity of the recombinant proteins was verified by
immunoblotting with HCV-infected sera. Moreover, binding
of recombinant proteins was probed for the histidine tags
using anti-His antibodies. It was determined that these gene and (B) NS5A, and phylogenetic trees revealed that the
e 1a.
Figure 3. Multiple sequence alignment of the (A) isolated NS3 protease and (B) NS5A with six different hepatitis C virus geno-
types, and the mutation occurred in the new 1a variant.
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tagged-NS5A were 38 and 68 kDa, respectively (Fig. 4).
Protein purification
Several kinds of strategies were used to express soluble
heterologous proteins in different strains of E. coli; there-
fore, acquisition of solubility is the most important issue in
protein purification. In the present study, two different
strategies were used to purify recombinant proteins. The
first purification method was carried out to purify
expressed proteins under nondenaturing condition in order
to obtain soluble form of proteins, whereas the second
procedure enabled preparation of the lysate and Ni-NTA
chromatography column under denaturing condition. In
this process, proteins were washed and eluted by non-
denaturing buffers. This system is a protein-activity-
preserving method for purifying insoluble proteins.
Present attempts to purify soluble NS5A using the first
strategy was successful when NS3 protease was exclusively
associated with the insoluble pellet fraction and no secre-
tion of it was recognized in the supernatant culture; thus,
urea was used to solubilize it. NS3 protease was purified
under denaturing condition and eluted using nondenaturing
buffers. Purified proteins were verified by western blotting.
Protein assay
Bovine serum albumin was used as the protein standard
concentrationversus protein samples. The standardcurvewas
drawn by plotting the average absorbance (562 nm) of each
bovine serum albumin standard. The standard curve was usedto determine the protein concentration of each sample. Since
the absorbance at 562 nm was 0.035 and 0.034, respectively,
for purified NS5A and NS3 protease, the concentrations of the
samples according to the standard curve were 0.83 mg/mL for
NS3 protease and 0.86 mg/mL for NS5A.
Regarding the fact that protein samples were diluted 1:1
with working solution, it can be concluded that 0.83 and
0.86 mg of recombinant NS3 protease and NS5A, respec-
tively, can be purified from 1 L of cell culture.
Anti-HCV antibody responses against NS3 protease
and NS5A
HCV-positive (100) and HCV-negative (50) sera were tested
by indirect ELISA method, using the recombinant fusion
proteins. HCV-infected sera were serially diluted in PBS and
used as the primary antibody for detecting the immune
reactivity of purified recombinant proteins. The cutoff
point was calculated as the mean value of the 50 samples
from healthy blood donors plus four randomly chosen
standard deviations. On the basis of the cutoff value,
positive and negative results were distinguished. From the
100 HCV-positive sera used for ELISA test, 73% detected NS3
protease and 58% recognized NS5A (Fig. 5).
In the next step, both purified proteins were coated onto
the same ELISA wells, and 79% of HCV-infected sera
recognized both antigens.
Genotype dependence of the serological reactivity
Serological reactivity of sera from 25 patients infected with
genotype 1a, 25 patients infected with genotype 3a, and 17
Figure 4. Purified recombinant NS3 protease and NS5A, respectively, 38 and 68 kDa, detected by (A) HCV-positive sera (anti-
HCVs) and (B) anti-His antibody. Lane 1 (A): purified NS5A recognized by antibodies in positive sera; Lane 2 (A): purified NS3
protease recognized by antibodies in positive sera; Lane 1 (B): purified NS5A detected by anti-His; and Lane 2 (B): purified NS3
protease detected by anti-His. Lane M is a protein marker. HCV Z hepatitis C virus.
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NS5A from genotype 1a was assessed by indirect ELISA test.
NS3 protease and NS5A were used separately as coating
antigens for detecting antibody responses against each
individual protein using genotype-categorized sera.
Genotype-dependent responses to recombinant proteins
were assessed. In order to detect the genotype sensitivity,
series dilution samples were used in the assay.Figure 5. Anti-HCV antibody responses to purified NS3 protease a
positive sera has been investigated by enzyme-linked immunosorbFrequencies of serological reactivity of genotype 1a, 3a,
and 1b antisera to recombinant NS3 protease were 72%,
68%, and 64.7%, respectively. Similarly, the anti-HCV anti-
body responses to recombinant NS5A was genotype
dependent, and the frequencies of reactivity of type 1a,
3a, and 1b sera were 52%, 56%, and 47%, respectively.
Variation in immune response according to the specific
genotype is shown in Table 2.nd NS5A. Prevalence of antibodies against HCV proteins in 100
ent assay with recombinant proteins. HCV Z hepatitis C virus.
Table 2 Genotype-specific responses against recombinant
proteins
Genotype No. of sera Percentage of positive
immune response
NS3 protease NS5A
1a 25 72 52
1b 17 64.7 47
3a 25 68 56
The prevalence of anti-HCV antibodies was assessed by indirect
enzyme-linked immunosorbent assay using recombinant NS3
protease and NS5A in 67 patients with chronic HCV infection of
three different genotypes. HCV Z hepatitis C virus.
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Expression of recombinant HCV proteins has always been
troublesome. In the present work, we assessed the immu-
noreactivity of full-length NS3 protease and N-terminally
truncated NS5A. We isolated, cloned, expressed, and puri-
fied recombinant HCV proteins of genotype 1a, using the
Champion pET Directional TOPO expression system.
Recombinant proteins were expressed with N-terminal His-
patch thioredoxin. The main goal of fusion recombinant
proteins with thioredoxin was to increase translation effi-
ciency and solubility of heterologous proteins expressed in
E. coli. This is the first time that NS5A has been expressed
with thioredoxin fusion tag. Previously, NS5A was expressed
using pET-ubiquitin expression system39 or with N-terminal
glutathione S transferase tag.40 According to our results,
expression of HCV proteins with thioredoxin tag is an effi-
cient approach to produce a significant amount of soluble
proteins, and it also facilitates one-step purification of HCV
proteins.
The selected host strain for expression, BL21 Star (DE3)
E. coli, contains lambda DE3 lysogen, which allows high-
level expression of T7-regulated genes. Among all possible
pET expression vectors, we used pET TOPO 102/D, which
contains a T7lac promoter that inhibits the basal expression
of the gene of interest in BL21 Star (DE3) cells. This is very
crucial for expressing NS3 protease because the basal
expression of this protease may lead to plasmid instability
and cell death.
Recombinant protein yield is correlated with transcrip-
tion efficiency of the corresponding gene. BL21 Star (DE3)
carries a mutated rne gene that encodes a truncated RNase
E. The C-terminally mutated enzyme lacks the ability to
degrade mRNA, resulting in an increase in mRNA stability.
We confirmed the presence of NS3 protease and NS5A
mRNAs by performing a qualitative real-time RT PCR.
Enhancement of mRNA stability enables us to increase the
yields of the recombinant proteins because of the increased
translation efficiency.
In the current work, we expressed N-terminally trun-
cated NS5A. Amino acid residues in the N-terminal region of
NS5A create an amphipathic membrane-anchored domain.
The presence of this a-helix decreases the solubility of
NS5A. In a previous study, truncated NS5A was produced by32 amino acid deletions from the N-terminal domain of
NS5A.39 Huang et al removed 30 amino acids related to the
anchor domain of NS5A and subsequently two more amino
acids were deleted from the protein sequence, which might
have led to potential alterations in the structure and
function of the recombinant NS5A. In the present study, 24
amino acids were removed from the anchor domain of NS5A
at the N-terminal end. This strategy resulted in an increase
in the solubility of NS5A, which enabled us to purify the
native form of NS5A.
According to protein assay results, from a 1 L culture of
induced BL21 Star (DE3) cells 0.83 and 0.86 mg of purified
NS3 protease and NS5A, respectively, were obtained. It
should be noted that most of the papers did not report the
protein yield. Comparing with same studies, we developed
a more efficient procedure that gives high protein yield and
purity in a very convenient way. For instance, in another
study, purification of the NS3 protein under denaturing
condition resulted in only about 0.3 mg/L bacterial
culture.41 In comparison to the aforementioned study, one
of the significance of our study was that we used native
buffers without urea and chaotic agents during the wash
and elution steps, in order to provide the possibility of
refolding the recombinant protein. In 2003, Hou et al
devised a eukaryotic expression system for NS3 protease
and could harvest 0.2 mg of recombinant protein from
5  107 insect cells.42
According to the migration of recombinant tagged-fusion
proteins in the SDS-polyacrylamide gel, molecular weights
of full-length NS3 protease and truncated NS5A were 38 and
68 kDa, respectively. Since the molecular weight of His-
patch thioredoxin is 16 kDa, we determined the exact
molecular weights of recombinant NS3 protease and NS5A:
22 and 52 kDa, respectively. We further ascertained the
immunoreactivity of the recombinant proteins by western
blot using HCV-positive sera to detect antibody responses
against each expressed. Our observed results confirmed the
existence of seroreactive epitopes within the recombinant
NS3 protease and NS5A.
It is of great importance to screen and diagnose HCV as
early as possible. After exposure to HCV, antibodies to HCV
are detectable by enzyme immunoassay. The third-
generation (G3) assay, which is currently recommended
for the diagnosis of HCV infection, is evidently superior in
both sensitivity and specificity to those of the second- and
the first-generation assays.43 Third-generation enzyme
immunoassay includes seroreactive epitopes of HCV core,
and NS3, NS4, and NS5A proteins,44 and it is confirmed that
this generation enhances the reliability of anti-HCV
detection earlier in the course of infection. There are
nonspecific regions inside each HCV protein. It is well
established that amino acid sequence of an antigen and the
way the epitope is presented to the immune system can
affect the immunogenecity of the peptide. Prior to or
simultaneously with seroconversion to HCV core protein,
antibodies to NS3 are detectable in the sera of HCV-
infected individuals. Many previous studies emphasized on
evaluating the antigenicity of the two-thirds of N-terminal
domain of NS3 protein, which includes the C-terminus part
of protease domain and the ATPase/helicase domain. It has
been proved that during the early phase of HCV infection,
the aforementioned regions of NS3 are serologically
290 M. Alaee et al.reactive.45 Taking this into account, we decided to inves-
tigate the serological reactivity of full-length NS3 protease
in order to test the antigenic sensitivity and specificity of
the new recombinant protein. The nonstructural protein 5
contains several substantial antigenic epitopes that can be
used to discern anti-HCVs; hence, NS5A is currently used in
the third generation of anti-HCV ELISA kits.
We used recombinant HCV NS3 protease and NS5A from
genotype 1a to test antibody responses to each single
protein and subsequently used both proteins together as
a coating antigen in ELISA plates. In order to reveal the
relative immunogenicity of each protein, we used a similar
amount of each purified recombinant protein. Our results
illustrate that of 100 HCV-infected sera with different
genotypes, 73% recognized the full-length recombinant NS3
protease, 58% detected NS5A, and 78% distinguished both
proteins. The HCV NS3 protease and NS5A produced in
prokaryotic system were both immunoreactive. Immuno-
reactivity of our recombinant protein was better in
comparison with other similar studies. A recent study re-
ported 68% and 53% immune response to NS3 and NS5,
respectively.37 Moreover, in another study, the highest
positivity response to NS5A antigen was 61%.46
For developing a commercial immunoassay, sensitivity,
specificity, and reproducibility are of great significance.
Fortunately, the reproducibility of the test was efficiently
high and results were similar when the test was repeated.
One of the most important aims of the present study was
to determine the genotype-specific serological reactivity to
NS3 protease and NS5A. With regard to HCV genotypes, our
analysis of immunoresponses to recombinant antigens indi-
cated no major difference between genotype 1a and other
genotypes. Our results demonstrated a substantial higher
immunoresponse to NS3 protease in all HCV genotypes in
comparison to the median antibody responses to recombi-
nant NS5A. According to these findings, it can be deduced
that reactivity of sera to homologous recombinant antigens is
not substantially stronger than heterologous types.
In conclusion, NS3 protease and NS5A genes were effi-
ciently expressed using TOPO expression system for the first
time, and the identity and immunoreactivity of the
recombinant proteins were validated using immunoblot. A
rapid one-step purification of recombinant proteins in the
absence of chaotic agents makes it possible to harvest
a substantial amount of both proteins. Producing greater
amount of recombinant proteins will facilitate inhibitor
designing against NS3 protease as a target for HCV treat-
ment and provide a good source to investigate each and
every single function of NS5A, since many roles of this
protein is still unknown. Furthermore, purified recombinant
proteins were found to be suitable for detecting antibodies
against HCV proteins in HCV-infected patients. In vitro
antigenic activity of our recombinant proteins makes them
suitable for improving the current anti-HCV screening and
diagnosing assays. Results of this study suggest that the
TOPO expression system has the potential and flexibility for
presentation of immunoreactive epitopes of HCV proteins.
Recombinant proteins from this study will also enable the
analysis of cell-mediated responses in HCV infection. High-
level expression of both recombinant proteins and single-
step purification process makes this strategy a very cost-
effective approach in order to produce other viral proteins.Conflicts of interest
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